30053
document
Comparison of the effect of gonadotropin-releasing hormone analog ( Diphereline ) and Cabergoline ( Dostinex ) treatment on uterine myoma regression . OBJECTIVE To investigate the effect of cabergoline ( Dostinex , a dopamine agonist ) on the myoma growth compared to Diphereline ( a gonadotropin-releasing hormone agonist ) . METHODS This study took place in the Department of Obstetrics and Gynecology of Tabriz University of Medical Sciences , Tabriz , Iran from July 2004 to December 2005 . Fifty women with uterine myoma , who met the criteria of the study thoroughly , were randomly allocated into 2 equal groups to take either Diphereline or Cabergoline . The first Group took 3.75 mg of Diphereline 4 times every 28 days and the second group took 0.5 mg of Cabergoline once a week for 6 weeks . RESULTS The Cabergoline was well tolerated and fewer adverse effects were noted . The tumor regressed significantly and volume reduction rate of individual tumor nodule varied from 46-53 % . The gonadotropin releasing hormone agonist group all responded to the treatment , and volume reduction rate of the individual tumor nodule varied from 21-97 % . The extent of tumor shrinkage was positively correlated to the number of nodules ( p=0.881 , p < 0.005 and 0.701 , p < 0.005 ) . CONCLUSION In light of therapeutic efficacy and few adverse effects , the dopamine agonists may hold promise as novel treatment modalities for leiomyoma . Further studies are warranted to determine the optimal strategy for the treatment of leiomyoma through these agents .
30054
Intervention_Pharmacological
gonadotropin-releasing hormone analog ( Diphereline )
30055
Intervention_Pharmacological
Cabergoline ( Dostinex )
30056
Intervention_Pharmacological
cabergoline ( Dostinex , a dopamine agonist )
30057
Intervention_Pharmacological
Diphereline ( a gonadotropin-releasing hormone agonist )
30058
Intervention_Pharmacological
Diphereline
30059
Intervention_Pharmacological
Cabergoline
30060
Intervention_Pharmacological
Diphereline
30061
Intervention_Pharmacological
Cabergoline
30062
Intervention_Pharmacological
Cabergoline
30063
Intervention_Pharmacological
gonadotropin releasing hormone agonist
30064
Intervention_Pharmacological
dopamine agonists
30065
Outcome_Other
well tolerated
30066
Outcome_Adverse-effects
fewer adverse effects
30067
Outcome_Physical
tumor regressed significantly
30068
Outcome_Physical
volume reduction rate of individual tumor nodule
30069
Outcome_Physical
volume reduction rate
30070
Outcome_Physical
tumor shrinkage
30071
Outcome_Physical
number of nodules
30072
Participant_Condition
uterine myoma regression
30073
Participant_Sample-size
Fifty women
30074
Participant_Condition
uterine myoma